tiprankstipranks
Shield Therapeutics PLC (GB:STX)
LSE:STX
UK Market

Shield Therapeutics Stock Analysis & Ratings

GB:STX Stock Chart & Stats

Day’s Range14.66p - 15.5p
52-Week Range39.10p - 163.90p
Previous Close15.2p
Volume123.53K
Average Volume (3M)660.59K
Market Cap31.69M
P/E Ratio-1.9
Beta1.64
Next EarningsSep 21, 2022
EPS ForecastN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price TargetN/A
Smart Score2
EPS (TTM)-0.09


Shield Therapeutics News

Currently, no data available
Please return soon. This page is being updated.

---

Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

GB:STX FAQ

What was Shield Therapeutics’s price range in the past 12 months?
Shield Therapeutics lowest stock price was 39.10p and its highest was 163.90p in the past 12 months.
    What is Shield Therapeutics’s market cap?
    Shield Therapeutics’s market cap is 31.69M.
      What is Shield Therapeutics’s price target?
      Currently, no data Available
      What do analysts say about Shield Therapeutics?
      Not enough analysts have published a price target to provide an average price target.
      When is Shield Therapeutics’s upcoming earnings report date?
      Shield Therapeutics’s upcoming earnings report date is Sep 21, 2022 which is in 126 days.
        How were Shield Therapeutics’s earnings last quarter?
        Shield Therapeutics released its earnings results on Aug 17, 2021. The company reported -4p earnings per share for the quarter, missing the consensus estimate of N/A by -4p.
          Is Shield Therapeutics overvalued?
          According to Wall Street analysts Shield Therapeutics’s price is currently Overvalued.
            Does Shield Therapeutics pay dividends?
            Shield Therapeutics does not currently pay dividends.
            What is Shield Therapeutics’s EPS estimate?
            Shield Therapeutics’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Shield Therapeutics have?
            Shield Therapeutics has 216,190,000 shares outstanding.
              What happened to Shield Therapeutics’s price movement after its last earnings report?
              Shield Therapeutics reported an EPS of -4p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -10.861%.
                Which hedge fund is a major shareholder of Shield Therapeutics?
                Currently, no hedge funds are holding shares in GB:STX

                ---

                Shield Therapeutics Stock Analysis

                Smart Score
                2
                Underperform
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10
                Price Target
                No data currently available

                Analyst Forecast

                N/A
                Currently Not Enough Data Available

                Blogger Sentiment

                N/A
                Currently Not Enough Data Available

                Hedge Fund Holdings

                N/A
                Currently Not Enough Data Available

                Insider Transactions

                N/A
                Currently Not Enough Data Available

                Retail Investors

                N/A
                Currently Not Enough Data Available

                News Sentiment

                N/A
                Currently Not Enough Data Available

                Technicals

                SMA
                Negative
                20 days / 200 days
                Momentum
                -72.85%
                12-Months-Change

                Fundamentals

                Return on Equity
                N/A
                Trailing 12-Months
                Asset Growth
                N/A
                Trailing 12-Months
                The Shield Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Shield Therapeutics PLC

                Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments which is based on key products include Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. It generates maximum revenue from Feraccru segment.

                ---
                Similar Stocks
                Company
                Price & Change
                Follow
                ImmuPharma
                ReNeuron Group
                Avacta Group plc

                Popular Stocks

                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis